Before looking into the role of ‘Gene Editing’ technology in cholesterol, let’s understand the basic of this technology. As the name suggests, editing or altering the gene (or genetic material), so as to get a new and/or modified expression of a particular gene which then results in a different phenotypic expression of that particular gene. This basic principle of Gene Editing technology is now under robust research for utilization in treatment of various health issues and ailments.
One such recent pilot study published in The New England Journal of Medicine is Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. In this article, it is informed that Phase 1 Trial of a new treatment using gene editing technology and CRISPR-Cas9 system showed promising results in managing cholesterol levels in the human body. CTX310 is the therapy which is a CRISPR-Cas9 gene-editing therapy.
Key features of this pilot study:
15 patients (aged 18-75) were involved in Phase 1 Trial.
CTX310 targeted the angiopoietin-like protein 3 (ANGPTL3), switching it off and thus helping in reduction of bad cholesterol (LDL) and triglycerides, thereby alleviating the risk of cardiovascular diseases as well.
Initial results showed around 50% reduction in LDL (low-density lipoprotein) and around 55% reduction in triglycerides.
CTX310 will enter into next trial phases later this year or earlier in 2026. This therapy is in consideration to be a permanent and one-time solution to deal with and lower down the high levels of LDL cholesterol and triglycerides in human body.
Can you enlist here some more gene-editing therapies and the disease for which they are being used or any such therapy currently in a particular clinical-trial phase?
Some gene-editing therapies in trials include CRISPR-Cas9 for sickle cell disease and β-thalassemia, CAR-T for cancers, EDIT-101 for Leber congenital amaurosis, and NTLA-2001 for transthyretin amyloidosis.
This is truly exciting! Seeing therapies like CTX310 use CRISPR Cas9 to lower LDL and triglycerides reminds us of the fascinating journey science has taken to benefit people and give them real and lasting hope. Similar gene-editing approaches are showing promise for conditions like familial hypercholesterolemia (PCSK9) and blood disorders such as sickle cell disease. What’s gratifying is that these aren’t just another lab report with complex terms. — They could mean fewer heart attacks, robust and long lives, and peace of mind for patients and families. These are some other examples of how Gene editing is turning hope into tangible solutions.
Exagamglogene autotemcel (Casgevy) – This has already been approved in some countries
after successful trials.
2.CRISPR Cas9 is used to edit hematopoietic stem cells for β thalassemia. & sickle cell
disease. Safety and efficacy are being explored in Ongoing Phase 1 trials.
This is a promising update. Gene editing is moving from theory to real clinical use, and CTX310 is a great example. Switching off ANGPTL3 and seeing such sharp drops in LDL and triglycerides is impressive, especially from a phase 1 trial.
This is a revolutionising study. Phase 1 has provided promising results. If Phase 2 & 3 also give trustable figures, this would be a great trial which will change the face of CV diseases management. The practicality (just once in a life time administration) of this therapy is the outstanding feature. No burden of compliance, regular monitoring will help patients very much.
Its great to see, how CRISPER-Cas9 editing gene is being employed in discovering new ways of treatment in healthcare- its ongoing application in altering management for conditions like- sickle cell anemia, thalassemia & cancer is really inspiring.
These developments highlight how gene editing is shifting treatment from lifelong management to one time, disease modifying therapies. The future of precision medicine looks incredibly promising.
CRISPR full form is Clustered regularly interspaced palindromic repeats (CRISPR) used in biomedical research. It correct errors in the genome.Cas 9 is the CRISPR associated 9 is the protein. It act like the molecular scissor
CRISPR-Cas 9 gene editing tool is not only employed in cholesterol-lowering therapy, it is a widely emerging tool that is being used in several other neurological disorders too. Some of the examples of such diseases where CRISPR-Cas 9 is under trial includes - Parkinson’s disease, Alzheimer’s, Huntington’s disease.
Gene-editing technology is a groundbreaking scientific advancement that can bring about a significant change in many lives, particularly in the treatment of diseases that are difficult to cure. If clinical trials prove successful, it could be a boon for people with high cholesterol, as uncontrolled cholesterol levels can lead to life-threatening conditions such as heart attacks and other related complications.
Totally amazing! Medicine is genuinely being revolutionized by gene editing. Treatments such as **EDIT-101** (CRISPR for Leber congenital amaurosis), **NTLA-2001** (CRISPR for transthyretin amyloidosis), and **ex vivo CRISPR-modified T-cells** for sickle cell disease and β-thalassemia are in different stages of trial in addition to CTX310 for cholesterol. Each stands for the possibility of long-term, focused solutions. Which gene-editing treatment most excites you, and how do you think it will influence personalized medicine going forward?
Gene editing therapies are really expanding beyond cholesterol management. For example, CRISPR-based treatments like Casgevy have already been approved for sickle cell disease and beta thalassemia, showing how powerful this approach can be. There are also trials exploring gene editing for rare metabolic disorders, kidney diseases, and even eye conditions. What’s striking is that many of these therapies aim to be one-time, permanent solutions rather than lifelong medication. Of course, the challenge remains in ensuring safety, precision, and ethical use, but the clinical pipeline is growing fast. It feels like we’re at the start of a new era in medicine.
Gene editing is opening new doors in cholesterol management.
By targeting genes involved in lipid metabolism, emerging therapies aim to provide long-term control of high cholesterol—especially for patients who don’t respond well to conventional treatments.
Medicine is genuinely being revolutionized by gene editing. Treatments such as **EDIT-101** (CRISPR for Leber congenital amaurosis), **NTLA-2001** (CRISPR for transthyretin amyloidosis), and **ex vivo CRISPR-modified T-cells** for sickle cell disease and β-thalassemia are in different stages of trial in addition to CTX310 for cholesterol. Each stands for the possibility of long-term, focused solutions. Which gene-editing treatment most excites you, and how do you think it will influence personalized medicine going forward? 
